Nanoparticle vaccine shown to block range of flu strains in pre-clinical study 25 March 2021 | By Victoria Rees (Drug Target Review) A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
Three common antiviral drugs effective against SARS-CoV-2 in vitro 25 March 2021 | By Victoria Rees (Drug Target Review) A team has shown that tilorone, quinacrine and pyronaridine are effective at inhibiting the replication of SARS-CoV-2 in vitro.
Organ-on-a-chip model developed to aid sickle cell disease treatment 25 March 2021 | By Victoria Rees (Drug Target Review) Researchers have developed a novel organ-on-a-chip model of sickle cell disease to improve personalised medicine.
First 3D images of Survival Motor Neuron complex visualised 25 March 2021 | By Victoria Rees (Drug Target Review) Researchers have imaged the entire Survival Motor Neuron complex using X-ray diffraction analysis, among other techniques.
Cell-based assays market set to be worth $22bn by 2025 24 March 2021 | By Victoria Rees (Drug Target Review) New research has shown that the cell-based assays market will grow at a CAGR of 8.1 percent between 2020 and 2025.
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir 24 March 2021 | By Victoria Rees (Drug Target Review) Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Deactivating gene could boost immunotherapy for head and neck cancer 24 March 2021 | By Victoria Rees (Drug Target Review) Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Lung-on-a-chip models enable advanced study of immune response 24 March 2021 | By Victoria Rees (Drug Target Review) Researchers have reviewed lung-on-a-chip technologies, finding they are useful for representing the various disease pathologies.
Polymerised oestrogen provides neuroprotection in pre-clinical study 23 March 2021 | By Victoria Rees (Drug Target Review) The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
Conformational equilibria in GPCRs provides clues about activation 23 March 2021 | By Victoria Rees (Drug Target Review) Having revealed the activation mechanism and functional states of A2AR signalling, a GPCR, researchers say this could aid drug discovery.
‘Zinc finger’ gene therapy could help to treat Alzheimer’s disease 23 March 2021 | By Victoria Rees (Drug Target Review) Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
Cannabinoids could reduce essential tremors in patients 22 March 2021 | By Victoria Rees (Drug Target Review) A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Chemical cocktail creates new avenues for generating muscle stem cells 22 March 2021 | By Victoria Rees (Drug Target Review) A combination of chemicals has shown promise in pre-clinical studies to produce muscle stem cells, giving hope for regenerative medicine.
Molecular technique could provide key for SARS-CoV-2 drug discovery 22 March 2021 | By Victoria Rees (Drug Target Review) Researchers are using a new method to isolate the complex between SARS-CoV-2 and the ACE2 receptor to keep it embedded in the cell membrane.
Rhesus macaque model of Alzheimer’s disease developed 19 March 2021 | By Victoria Rees (Drug Target Review) Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
